TY  - JOUR
AU  - Schmutz, Maximilian
AU  - Zucknick, Manuela
AU  - Schlenk, Richard F
AU  - Mertens, Daniel
AU  - Benner, Axel
AU  - Weichenhan, Dieter
AU  - Mücke, Oliver
AU  - Döhner, Konstanze
AU  - Plass, Christoph
AU  - Bullinger, Lars
AU  - Claus, Rainer
TI  - Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen.
JO  - Clinical epigenetics
VL  - 15
IS  - 1
SN  - 1868-7075
CY  - [Erscheinungsort nicht ermittelbar]
PB  - BioMed Central
M1  - DKFZ-2023-02175
SP  - 171
PY  - 2023
N1  - #EA:B370#LA:B370#
AB  - Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. Dysregulation of the epigenetic machinery is a significant contributor to disease development. Some AML patients benefit from treatment with hypomethylating agents (HMAs), but no predictive biomarkers for therapy response exist. Here, we investigated whether unbiased genome-wide assessment of pre-treatment DNA-methylation profiles in AML bone marrow blasts can help to identify patients who will achieve a remission after an azacytidine-containing induction regimen.A total of n = 155 patients with newly diagnosed AML treated in the AMLSG 12-09 trial were randomly assigned to a screening and a refinement and validation cohort. The cohorts were divided according to azacytidine-containing induction regimens and response status. Methylation status was assessed for 664,227 500-bp-regions using methyl-CpG immunoprecipitation-seq, resulting in 1755 differentially methylated regions (DMRs). Top regions were distilled and included genes such as WNT10A and GATA3. 80
KW  - AML (Other)
KW  - Azacytidine (Other)
KW  - DNA methylation patterns (Other)
KW  - DNA-methylation (Other)
KW  - Epigenetics (Other)
KW  - HMA-treatment (Other)
KW  - Predictive biomarker (Other)
KW  - Predictive signature (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37885041
DO  - DOI:10.1186/s13148-023-01580-z
UR  - https://inrepo02.dkfz.de/record/285002
ER  -